ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) has announced that thymosin beta 4 (Tß4) can activate a unique subpopulation of resident adult epicardial stem cells such that they recapture embryonic potential, proliferate, migrate and differentiate into functional heart muscle (cardiomyocytes), according to a research paper published online today in Nature. The study animals treated with Tß4 prior to injury had increased activation of these resident stem cells that functionally integrated into new heart muscle, suggesting that these cells needed to be “primed” prior to injury to effect activation.
